Workflow and throughput
Manufacturer-stated throughput is labelled as manufacturer-provided. Independent lab evaluation is tracked where available.
Evidence-centred evaluation for India
Evaluating Chinese biomedical technology for Indian professional users.
SinoBio Access helps Indian professional users evaluate Chinese biomedical technology through laboratory evaluation data, workflow and throughput information, TB and drug-resistance evidence, and regulatory and import guidance. Manufacturer-provided information is clearly labelled.
100% Sourced
Every parameter tagged to manufacturer IFU or study
Grade A~U
Multi-tiered evidence grading system
CDSCO & NTEP
Import and local evaluation pathways for India
Zero Bias
Transparent disclosure of evidence limits & gaps
Laboratory evaluation for India
How throughput, turnaround time and concordance data are organised for Indian labs.
TB & drug resistance
The iFIND TBR + IFQ workflow for tuberculosis molecular diagnostics, including detection of MDR/FQ markers.
Room-temp logistics
For Indian settings without continuous cold chain, room-temperature lyophilized stability claims are verified.
Featured: TB molecular diagnostics — iFIND TBR + IFQ
Automated qPCR closed-cartridge workflow for high-burden diagnostic settings.
iFIND TBR + IFQ Molecular Workflow
-
1 SpecimenSample Collection & Lysis Sputum or alternative respiratory specimen. Automated or manual lysis per protocol.
-
2 Cartridge 1iFIND TBR (Primary Screen) Detection of M. tuberculosis complex DNA and rifampicin-resistance markers.IS6110 IS1081 / IS1087 rpoB
-
3 Cartridge 2iFIND IFQ (MDR Profiling) Expanded resistance detection for isoniazid and fluoroquinolones.katG inhA gyrA
-
4 ReportClinical Interpretation Integrated fluorescent quantification evaluated together with clinical context.
Evidence Boundary Note:
All parameters are manufacturer-provided (iFIND). IS1081/IS1087 target conflict and detection time discrepancy (85 min vs ≤120 min) are unresolved. Local regulatory status is not verified. This diagram is for educational purposes.
Indian Clinical Context
Early evidence cluster for molecular tuberculosis detection, including detection of drug resistance markers (RIF, INH, FQ). All technical parameters are provided by the manufacturer and are clearly labelled. Local CDSCO registration status is not verified.
- Target Genes: IS6110, IS1081/IS1087, rpoB, katG, inhA, gyrA
- Turnaround Time: 85 mins (Claimed) vs ≤120 mins (Doc discrepancy)
- Cartridge Format: Lyophilized reagents stable at 2-30°C
Solution areas
Technologies organised by clinical area, open for evaluation in India.
Solution Area
Molecular Diagnostics
Solution Area
Tuberculosis Drug Resistance
Solution Area
Immunodiagnostics
Solution Area
Point-of-Care Testing
Solution Area
Laboratory Automation
Regulatory and import questions for India
CDSCO registration
Is the product registered with the Central Drugs Standard Control Organisation (CDSCO)? Default status is "not checked" until verified.
Local regulatory status not verified
Import permissions
Import may be permitted for evaluation even before full registration. Import status is tracked per product and defaults to "not checked".
Evaluation checklist
Use the laboratory evaluation checklist when assessing Chinese technology in an Indian lab setting.
Technical documentation
Technical documents are available on request through a signed, time-limited link. No public download.
Evidence updates
Receive notifications when new evidence or verification status changes are published. Double opt-in.
Submit an unmet need
Tell us about a clinical or laboratory need that current options do not meet for the Indian context.